Sanofi completes takeover of Bioverativ

Sanofi has announced the completion of its previously-announced acquisition of Bioverativ, a deal worth $11.6 billion (GBP 8.39 billion).

Bioverativ was created as a spin-off from Biogen in early 2017, and offers a range of extended half-life therapies for haemophilia, including Eloctate and Alprolix. These drugs represented the first major advancements in haemophilia in nearly two decades when first launched.

The acquisition of Bioverativ provides Sanofi with a strong position in the growing haemophilia market and will help the company expand its presence in specialty care. 

Specifically, the purchase means Sanofi now owns a promising compound currently undergoing phase III testing for cold agglutinin disease, and early-stage research programmes and collaborations for blood disorders such as sickle cell disease and beta thalassemia.

Olivier Brandicourt, Sanofi's chief executive officer, said: "Through a series of three strategic transactions – the addition of Bioverativ, our planned acquisition of Ablynx and our agreement for fitusiran – we are well on our way to creating a leading franchise in the field of rare blood disorders."

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.